How We Work
Clinical Impact of Molecular Diagnostic
Evaluate the clinical impact of a new molecular diagnostic for use in interstitial lung disease.
Choice model based on array of sensitivity and specificity levels to gauge minimum and optimal performance necessary to drive a change in diagnostic behavior and reduce the number of invasive diagnostics.
Approved for IRB.
Threshold sensitivity and specificity levels identified as well as pros and cons of two-state versus three-state classifier.
Presented at ATS 2015.
Company is moving forward with development plan.
Commercial Diligence Prior to Asset Acquisition
Define value proposition for new drug to be used to treat acute HE in hospitalized patients.
Term sheet had to be submitted within 10 business days.
Interwoven and iterative qualitative and quantitative research initiated and completed within 14 days
Multiple facets explored in tandem: patient pathway, efficacy and health economic endpoint exploration (ICU/LOS), pricing, formulary/restriction.
Characterized value proposition and use cases; company moving forward with acquisition.
Hospital Chart Audit for FXa Anticoagulant Reversal Drug
Identify rate of life-threatening or uncontrolled bleeds at major hospitals characterized by patient factors, bleed site, and treating physician specialty.
Secondary data sources not useful; thousands of ICD-10 codes for life-threatening bleeding events.
No analog drugs to guide market sizing or frequency of admissions.
Customized algorithm specific to anti-coagulant-related bleeding events that could be executed across hospital EMRs.
Designed data collection tool that could be completed by hospital pharmacists who were proficient in designing searches for their EMRs; hospital and patient-level data.
Write Visual Basic for Applications (VBA) program to aggregate data and automate analytics.
Recruit a panel of hospital pharmacists to participate in longitudinal research (monthly and quarterly).
Since 2016, findings have been continuously integrated into corporate forecast, announced on earnings calls and input into manufacturing planning.
Patient Journey in Diagnosis of Idiopathic Pulmonary Fibrosis
Characterize the patient journey of interstitial lung disease as they seek diagnosis.
In collaboration with the Pulmonary Fibrosis Foundation (PFF), research conducted with members of the PFF and Inspire Online Community to explore their diagnostic pathway including testing, misdiagnosis, unnecessary treatment, referral patterns, and timeline.
Documented significant delays in diagnosis and diagnostic errors.
Presented at PFF annual meeting 2015.
Call to action put forth at the annul PFF meeting with agreement to prioritize development of improved testing options.
Market Size and Launch Forecast in Orphan Drug Market
Estimate the market size and develop a forecast for new drug to treat periodic paralysis (PP).
No ICD-10 code for PP, market had never been sized, no drugs indicated for treatment.
Treating physicians concentrated in small number of academic medical centers.
Patients not organized into advocacy groups.
Integrated analysis including observational data analysis, primary market research with treating physicians, and patient pathway research with patients.
Developed revenue forecast model designed in alignment with PP patient health states. Dynamic, Excel-based model linked to sales force performance reporting system. Product launched successfully; base case targets exceeded.
Novel Approach to Branding in the Toxin Market
Ideate and optimize words, phrases, and language to leverage the strengths of a highly developed and sophisticated market while effectively differentiating the brand.
Developed a novel research methodology incorporating the principles of Centrality Versus Distinctiveness as presented in HBR 2015 (Dawar et al).
Executed with patients and physicians.
Identified central message elements currently used across the category that are motivating and should be maintained.
Resulted in significant cost and resource savings, as research revealed that re-branding the class would not drive share of new drug.
Identified distinct messages/descriptors that should be used to maximize differentiation of brand and motivate use.
Competitive Positioning in Multiple Sclerosis (US and EU)
Track market positioning and impact of new biologic to evaluate impact on launch strategy in future MS market.
Six competitive products ahead in pipeline, dominant pharma company launched rising blockbuster in 2018 potentially disrupting intended treatment pathway for target patient population and dampening success of launch.
US and EU survey fielded with MS Centers of Excellence and community neurologists.
Hypothesis that competitive launch would impact later line treatments, but not intended position for client’s product, was rejected.
Client initiated scenario planning to prepare for various trajectories of launch and pipeline products in market.